The clinical utility of biomarkers such as PD-L1 expression, tumor mutation burden (TMB), tumor infiltrating lymphocytes, and liquid biopsy biomarkers such as peripheral blood neutrophil-to-lymphocyte ratio or circulating tumor DNA, varies greatly among cancer types and treatment settings [3, 4]. This evidence concerns the gene CD274 and cancer.